Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

TEAM IIb trial results: Adjuvant ibandronate in early breast cancer

SABCS 2016

6 - 10 Dec 2016

Published: 9 Dec 2016

Views: 2462

Rating:

Save

Prof Sabine Linn - Netherlands Cancer Institute, Amsterdam, The Netherlands

Prof Linn presents data at the 2016 San Antonio Breast Cancer Symposium from the TEAM IIb trial, in which post-menopausal women with hormone receptor positive breast cancer, with no metastases, were treated with 3 years of adjuvant bisphosphonate therapy.

She describes no proof of statisically significant benefit of 3 years of ibandronate, with a slight increase in gastrointestinal side effects, and non-significant trend towards improved disease free survival and reduced bone metastases.

Related Videos

Breast cancer survivorship

Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg

Breast cancer survivorship ( Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

The added value of integrative medicine

Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos

The added value of integrative medicine ( Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

The Southeast Asian Breast Cancer Symposium; background, aims and successes

Carolyn Taylor - Executive Director, Global Focus on Cancer

The Southeast Asian Breast Cancer Symposium; background, aims and successes ( Carolyn Taylor - Executive Director, Global Focus on Cancer )

The current status of multiple myeloma diagnosis and treatment

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer